Berlex Bonefos Meeting For Breast Cancer Metastases Cancelled
This article was originally published in The Pink Sheet Daily
Executive Summary
It is the second time an FDA advisory committee meeting for Bonefos has been cancelled. The oncologics committee will still meet Dec. 1 to review Ilex/Enzon’s Marqibo and Ilex’ Clolar.
You may also be interested in...
Berlex’ Bonefos “Approvable”
Berlex' oral non-amino bisphosphonate Bonefos (clodronate) is "approvable" at FDA for breast cancer bone metastases
FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.